Search for content, post, videos
Advertisement

Trill Impact Ventures co-leads series B financing round in May Health

Together with Bpifrance, Trill Impact Ventures has co-led a USD 25 million series B financing round in May Health, a French-American medical device company targeting Polycystic Ovary Syndrome (PCOS) related infertility.

The round also saw participation from existing May Health investor Sofinnova Partners. Proceeds will advance the clinical development of May Health’s innovative device, as well as reaching CE marking that will enable market introduction in select European countries.

We see May Health as a great example of a company where commercial opportunity and social impact go hand in hand.”

“We see May Health as a great example of a company where commercial opportunity and social impact go hand in hand. Trill Impact is excited to collaborate with the May Health team and its investors to bring their innovative product to women who have suffered from a lack of treatment options for too long,” says Nina Rawal, Co-Head of Trill Impact Ventures and Partner at Trill Impact Advisory.

Read more: Trill Impact’s perspective when it comes to financing & supporting rare disease companies – NLS No 02 2024, out now!

May Health

May Health offers a novel approach to PCOS-related fertility and the upcoming REBALANCE study aims to demonstrate Ovarian Rebalancing as a safe and simple treatment option for activating natural ovulation.

In conjunction with the financing Nina Rawal will join May Health’s board of directors, and Bita Sehat, Senior Investment Director at Trill Impact Advisory, will join as an observer.

Photo of Nina Rawal: Trill Impact

Advertisement